-
Whole Genome Sequencing of Liver Cancers
Study
EGAS00001002408
-
RNA-seq of Glioblastoma stem cells
Study
EGAS00001003070
-
RNA sequencing data from glioblastoma primary cell lines treated with indisulam
Study
EGAS50000000680
-
Microbiota 16S sequencing study in NSCLC patients eligible for surgery without neoadjuvant treatment
Study
EGAS00001004728
-
Persistent Mutation Burden Drives Sustained Anti-Tumor Immune Responses
Study
EGAS00001006660
-
Single-cell multi-omics of relapse/refractory multiple myeloma patients (Hipo K08K/H067/K43R)
Study
EGAS00001006538
-
A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.
Study
phs000210
-
Elucidating Transcription Regulation by Epigenetics in Neuroblastoma
Study
phs001831
-
NHLBI GO-ESP: Family Studies (Hematological Cancers)
Study
phs000632
-
DNA Methylation in Prostate Tumor and Paired Benign Tissue for African and European Ancestry Men
Study
phs003516
-
Dynamics of multiple resistance mechanisms in plasma DNA and their clinical implications for NSCLC patients receiving EGFR-targeted therapies
Study
EGAS00001002908
-
NEOPREDICT-Lung: Neoadjuvant Immunotherapy for Resectable NSCLC
Study
EGAS00001007753
-
Integrative analysis reveals a macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer
Study
EGAS50000000809
-
Intra-tumor heterogeneity of localized lung adenocarcinomas defined by multi-region sequencing
Study
EGAS00001000930
-
Deep single-cell RNA sequencing data for 11138 T cells from tumour, adjacent normal tissue and peripheral blood of treatment-naive CRC patients. The DATA ACCESS AGREEMENT is provided at https://github.com/zhangyybio/single-T-cell-data-access. Applicants can request access to the data by directly downloading it or by sending an email to cancerpku@pku.edu.cn. The process that is used to approve an application includes verifying the institution, participants and research purposes of the application. In general this process will take about two weeks. In principal, any scientific research program complying with the laws and bioethic regulation policies of China will be approved.
Study
EGAS00001002791
-
Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric Cancer Risk
Study
phs002566
-
The Haplotype-Resolved Genome and Epigenome of the Aneuploid HeLa Cancer Cell Line
Study
phs000642
-
Resistance to anti-EGFR therapy in colorectal cancer
Study
EGAS00001000582
-
Characterization_of_genomic_landscape_of_Peripheral_T_cell_Lymphomas__not_otherwise_specified__PTCL_NOS_
Study
EGAS00001002057
-
Towards standardized whole exome sequencing (WES) for cancer patients: lessons from a multicentric pilot study
Study
EGAS00001007363
-
Immune heterogeneity in small cell lung cancer and vulnerability to immune checkpoint blockade
Study
EGAS50000000138
-
Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer
Study
EGAS00001006831
-
Development of actionable molecular targets and/or biomarkers for prognostication and patient stratification in gynecological cancer based on whole-exome sequencing and epigenomic analysis
Study
JGAS000642
-
The_effects_of_chemotherapy_and_radiation_in_human_oesophageal_epithelium__low_input
Study
EGAS00001007416
-
The_effects_of_chemotherapy_and_radiation_in_human_oesophageal_epithelium
Study
EGAS00001007417